FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent ...

Sawai Group Holdings (TSE:4887) is set to absorb a major expense for a patent infringement settlement involving Teriparatide Subcutaneous Injection, which has led the company to cut its operating ...

Ligand Pharmaceuticals (LGND) continues to deliver strong returns, with shares up approximately 74% since my last 'Buy' ...

SAWAI GROUP HOLDINGS Co., Ltd. ( ($JP:4887) ) has issued an announcement. Sawai Group Holdings Co., Ltd. has revised its financial forecasts for ...

SAWAI GROUP HOLDINGS Co., Ltd. ( ($JP:4887) ) has provided an update. Sawai Group Holdings Co., Ltd. has announced a financial provision for a ...

Learn more about whether Halozyme Therapeutics, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

For the first nine months of 2025, Gedeon Richter reported pharmaceutical revenues of HUF 668.8 billion (€1.67 billion), representing a 5.4% increase in constant exchange rates. However, third-quarter ...

Over half the women deemed very high risk are receiving treatment with therapies not recommended as first-line.

Learn more about whether BioMarin Pharmaceutical Inc. or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Around 14,000 women in England may soon be able to access a new treatment for osteoporosis after NICE backed routine NHS use of Theramex's Eladynos. The health technology assessment (HTA) agency said ...